WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012103163) COMPOSITIONS AND METHODS FOR TREATING CANCER WHILE PREVENTING OR REDUCING CARDIOTOXICITY AND/OR CARDIOMYOPATHY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/103163    International Application No.:    PCT/US2012/022460
Publication Date: 02.08.2012 International Filing Date: 25.01.2012
IPC:
A61K 39/395 (2006.01), A61K 48/00 (2006.01), A61K 31/455 (2006.01), A61P 35/00 (2006.01)
Applicants: THE CLEVELAND CLINIC FOUNDATION [US/US]; 9500 Euclid Avenue Cleveland, Ohio 44195 (US) (For All Designated States Except US).
HAZEN, Stanley, L. [US/US]; (US) (For US Only)
Inventors: HAZEN, Stanley, L.; (US)
Agent: BOND, Jason, R.; 2275 Deming Way, Ste 310 Middleton, Wisconsin 535362 (US)
Priority Data:
61/436,036 25.01.2011 US
61/468,292 28.03.2011 US
Title (EN) COMPOSITIONS AND METHODS FOR TREATING CANCER WHILE PREVENTING OR REDUCING CARDIOTOXICITY AND/OR CARDIOMYOPATHY
(FR) COMPOSITIONS ET MÉTHODES DE TRAITEMENT DU CANCER TOUT EN PRÉVENANT OU RÉDUISANT LA CARDIOTOXICITÉ ET/OU LA CARDIOMYOPATHIE
Abstract: front page image
(EN)The present invention provides methods for treating cardiotoxicity, cardiomyopathy, and/or cancer in a subject, as well as related compositions and kits, that employ a therapeutic agent, or a nucleic acid sequence encoding a therapeutic agent, selected from apolipoprotein A-1 (ApoA1), an ApoA1 mimetic, an agent that increases expression of ApoA1, or a binding agent specific for oxidized ApoA1, where the therapeutic agent is effective in preventing or reducing the level of cardiotoxicity and/or cardiomyopathy induced by the chemotherapeutic.
(FR)La présente invention concerne des méthodes de traitement de la cardiotoxicité, de la cardiomyopathie et/ou du cancer chez un sujet, ainsi que des compositions et kits apparentés, qui font appel à un agent thérapeutique, ou à une séquence d'acides nucléiques codant un agent thérapeutique, sélectionné à partir de l'apolipoprotéine A-1 (ApoA1), un agent mimétique de l'ApoA1, un agent qui accroît l'expression de l'ApoA1 ou un agent de liaison spécifique pour l'ApoA1 oxydée, l'agent thérapeutique étant efficace pour prévenir ou réduire le taux de cardiotoxicité et/ou le niveau de sévérité de la cardiomyopathie induit par une chimiothérapeutique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)